Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Issue 12 (2nd March 2015)

• Record Type: Journal Article
• Authors: Takahashi, Hideaki; Ikeda, Masafumi; Kumada, Takashi; Osaki, Yukio; Kondo, Shunsuke; Kusumoto, Shigeru; Ohkawa, Kazuyoshi; Nadano, Seijin; Furuse, Junji; Kudo, Masatoshi; Ito, Kiyoaki; Yokoyama, Masahiro; Okusaka, Takuji; Shimoyama, Masanori; Mizokami, Masashi
• Is Part Of: Hepatology research. Volume 45:Issue 12(2015:Dec.)
• Page Start: 1220
• Page End: 1227
• Publication Date: 2015-03-02
• Subjects: case survey -- chemotherapy -- hepatitis B virus -- hepatitis B virus DNA -- reactivation; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12496
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: The purpose of this multicenter cooperative study was to elucidate the clinical features of hepatitis B virus (HBV) reactivation by chemotherapeutic agents and the patient outcomes after HBV reactivation by a retrospective review of accumulated patients' medical records. Methods: Records of a total of 27 patients (hematological malignancy, 14 patients; solid tumor, 13 patients) from 11 institutions who were diagnosed between June 2005 and October 2010 as having HBV reactivation following chemotherapy were reviewed. Results: Of the 27 patients with reactivation, 16 patients were hepatitis B surface antigen (HBsAg) positive and 11 were HBsAg negative prior to the commencement of chemotherapy. Of the 11 patients who were HBsAg negative prior to the chemotherapy, 10 had hematological malignancies and one had a solid tumor. Of the 14 patients with hematological malignancies with HBV reactivation enrolled in the study, the reactivation occurred more than 12 months after the completion of chemotherapy in five patients (36%); on the other hand, none of the patients (0%) with solid tumors developed HBV reactivation more than 12 months after the completion of chemotherapy. Of the 24 patients who had acute liver dysfunction at the diagnosis of HBV reactivation, nine (38%) had severe hepatitis and seven (29%) died of liver failure. Conclusion: Most of the patients with HBV reactivation who were HBsAg negative prior to the chemotherapy had underlying hematological malignancies. Furthermore, patients with hematological malignancies often developed late‐onset HBV reactivation. The prognosis of patients who develop acute liver dysfunction as a complication of HBV reactivation is extremely dismal.